Quick Answer
ACADIA PHARMACEUTICALS INC reported Total Revenue of $1.07 billion for fiscal year 2025.
ACADIA PHARMACEUTICALS INC — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $1.07B +11.9% |
$957.80M +31.8% |
$726.44M +40.4% |
$517.24M +6.8% |
$484.14M +9.6% |
$441.75M +30.3% |
| Revenue (ASC 606) | $1.07B +11.9% |
$957.80M +31.8% |
$726.44M +40.4% |
$517.24M +6.8% |
$484.14M +9.6% |
$441.75M +30.3% |
| Net Income | $391.00M +72.7% |
$226.45M +469.5% |
-$61.29M +71.6% |
-$215.97M -28.7% |
-$167.87M +40.4% |
-$281.58M -19.7% |
| Diluted EPS | $2.30 +69.1% |
$1.36 +467.6% |
-$0.37 +72.4% |
-$1.34 -27.6% |
-$1.05 +41.3% |
-$1.79 |
| Total Assets | $1.56B +31.7% |
$1.19B +58.6% |
$748.96M +27.4% |
$587.81M -16.0% |
$700.12M -10.5% |
$782.62M -0.1% |
| Cash and Equivalents | $177.69M -44.4% |
$319.59M +69.4% |
$188.66M +64.3% |
$114.85M -22.1% |
$147.44M -54.8% |
$326.03M +71.9% |
| Stockholders Equity | $1.23B +67.5% |
$732.79M +69.7% |
$431.75M +7.8% |
$400.41M -26.0% |
$540.89M -13.7% |
$627.01M -10.3% |
| R&D Expense | $328.80M +8.4% |
$303.25M -13.8% |
$351.62M -2.8% |
$361.57M +51.0% |
$239.41M -25.0% |
$319.13M +32.8% |
| Operating Income | $104.81M -54.6% |
$230.79M +414.5% |
-$73.38M +67.2% |
-$223.60M -31.2% |
-$170.44M +40.5% |
-$286.59M -16.2% |
| Shares Outstanding | 170.31M +2.2% |
166.71M +1.3% |
164.65M +1.6% |
162.06M +0.7% |
161.01M +0.9% |
159.64M +2.8% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $278.63M | +11.3% | +5.3% |
| Revenue (ASC 606) | September 30, 2025 | $278.63M | +11.3% | +5.3% |
| Net Income | September 30, 2025 | $71.78M | +119.1% | +169.2% |
| Diluted EPS | September 30, 2025 | $0.42 | +110.0% | +162.5% |
| Total Assets | September 30, 2025 | $1.33B | +36.2% | +8.6% |
| Cash and Equivalents | September 30, 2025 | $258.00M | +66.3% | +1.7% |
| Stockholders Equity | September 30, 2025 | $917.27M | +58.9% | +11.5% |
| R&D Expense | September 30, 2025 | $87.83M | +31.9% | +12.7% |
| Operating Income | September 30, 2025 | $35.76M | +13.0% | +10.4% |
| Shares Outstanding | September 30, 2025 | 169.15M | +1.7% | +0.3% |
- ACADIA PHARMACEUTICALS INC reported Total Revenue of $1.07 billion for fiscal year 2025.
- ACADIA PHARMACEUTICALS INC showed an increase of +11.9% in Total Revenue compared to the prior fiscal year.
- ACADIA PHARMACEUTICALS INC reported Revenue (ASC 606) of $1.07 billion for fiscal year 2025.
- ACADIA PHARMACEUTICALS INC showed an increase of +11.9% in Revenue (ASC 606) compared to the prior fiscal year.
- ACADIA PHARMACEUTICALS INC reported Net Income of $391.00 million for fiscal year 2025.
- ACADIA PHARMACEUTICALS INC showed an increase of +72.7% in Net Income compared to the prior fiscal year.
- ACADIA PHARMACEUTICALS INC reported Diluted EPS of $2.30 per share for fiscal year 2025.
- ACADIA PHARMACEUTICALS INC showed an increase of +69.1% in Diluted EPS compared to the prior fiscal year.
- ACADIA PHARMACEUTICALS INC reported Total Assets of $1.56 billion for fiscal year 2025.
- ACADIA PHARMACEUTICALS INC showed an increase of +31.7% in Total Assets compared to the prior fiscal year.
- ACADIA PHARMACEUTICALS INC reported Cash and Equivalents of $177.69 million for fiscal year 2025.
- ACADIA PHARMACEUTICALS INC showed a decrease of -44.4% in Cash and Equivalents compared to the prior fiscal year.
- ACADIA PHARMACEUTICALS INC reported Stockholders Equity of $1.23 billion for fiscal year 2025.
- ACADIA PHARMACEUTICALS INC showed an increase of +67.5% in Stockholders Equity compared to the prior fiscal year.
- ACADIA PHARMACEUTICALS INC reported R&D Expense of $328.80 million for fiscal year 2025.
- ACADIA PHARMACEUTICALS INC showed an increase of +8.4% in R&D Expense compared to the prior fiscal year.
- ACADIA PHARMACEUTICALS INC reported Operating Income of $104.81 million for fiscal year 2025.
- ACADIA PHARMACEUTICALS INC showed a decrease of -54.6% in Operating Income compared to the prior fiscal year.
- ACADIA PHARMACEUTICALS INC reported Shares Outstanding of 170.31 million shares for fiscal year 2025.
- ACADIA PHARMACEUTICALS INC showed an increase of +2.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: